1,4-Dihydropyridines as calcium channel ligands and privileged structures

Cellular and Molecular Neurobiology

Volumn 23, Issue 3, 2003, Pages 293-303

  Triggle, David J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

1,4 dihydropyridines; Activator; Antagonist; Calcium channel; Ion channel; Pharmacophore; Privileged structure; Voltage gated ion channel

Indexed keywords

1,4 DIHYDRO 2 METHYL 6 PHENYL 4 (2 PHENYLETHYNYL) 3,5 PYRIDINEDICARBOXYLIC ACID 5 BENZYL 3 ETHYL ESTER; 1,4 DIHYDRO 2,6 DIMETHYL 4 (4 NITROPHENYL) 3,5 PYRIDINEDICARBOXYLIC ACID 3 [3 (4 METHOXYCARBONYL 4 PHENYL 1 PIPERIDINYL)PROPYL]AMIDE 5 METHYLAMIDE; 1,4 DIHYDROPYRIDINE DERIVATIVE; 9 (3 CYANOPHENYL) 3,4,6,7,9,10 HEXAHYDRO 1,8(2H,5H) ACRIDINEDIONE; 9 (3 CYANOPHENYL)HEXAHYDRO 1,8 ACRIDINEDIONE; AMLODIPINE; CALCIUM ANTAGONIST; CALCIUM CHANNEL; DILTIAZEM; FELODIPINE; G PROTEIN COUPLED RECEPTOR; ION CHANNEL; ISRADIPINE; LACIDIPINE; LERCANIDIPINE; NIFEDIPINE; NISOLDIPINE; NITRENDIPINE; POTASSIUM CHANNEL; SODIUM CHANNEL; UK 75505; UNCLASSIFIED DRUG; VERAPAMIL;

ANTIHYPERTENSIVE ACTIVITY; CARDIOVASCULAR SYSTEM; DRUG SELECTIVITY; DRUG STRUCTURE; HUMAN; PRIORITY JOURNAL; REVIEW; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ANIMALS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; CARDIOVASCULAR SYSTEM; CELL MEMBRANE; DIHYDROPYRIDINES; HUMANS; LIGANDS; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; RECEPTORS, CELL SURFACE;

EID: 0038390401     PISSN: 02724340     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1023632419813     Document Type: Review

References (58)

1. 2-receptor antagonists. Drug Design Deliv. 6:101-109.
2. Anrep, G. V., Kenawy, M. R., and Barsoum, G. S. (1949). The coronary vasodilator action of khellin. Am. Heart. J. 37:531-542.
3. Bossert, F., and Vater, W. (1989). 1,4-Dihydropyridines - a basis for developing new drugs. Med. Res. Rev. 9:291-324.
4. Catterall, W. A. (2000). Structure and function of voltage-gated calcium channels. Annu. Rev. Biochem. 65:493-531.
5. Catterall, W. A., Chandy, K. G., and Gutman, G. A. (2002). The IUPHAR Compendium of Voltage-Gated Ion Channels. IUPHAR Media, Leeds, United Kingdom.
6. Chin, M. H., Cioffi, C. L., Garay, M., Neale, R. F., Shetty, S. S., Del Grande, D., Mugrage, B., Sills, M. A., and Lipson, K. E. (1996). The unusual binding properties of the endothelin receptor antagonuit CGS 27830 distinguishes receptor/agonist interactions. J. Pharmacol. Exp. Ther. 276:74-83.
7. Cooper, K., Fray, M. J., Parry, M. J., Richardson, K., and Steele, J. (1992). 1,4-Dihydropyridines as antagonists of platelet activating factor 1. Syntheses and structure-activity relationships of 2-(4-heterocyclyl) phenyl derivatives. J. Med. Chem. 35:3115-3129.
8. Daly, J. W. (1998). Thirty years of discovering arthropod alkaloids in amphibian skin. J. Nat. Prod. 61: 162-172.
9. Drocourt, L., Pascussi, J.-M., Asenat, E., Fabre, J.-M., Maurel, P., and Vilarem, M.-J. (2001). Calcium channel modulators of the dihydropyridine family are human pregnane X receptor activators and inducers of CYP3A, CYP2B, and CYP2C in human hepatocytes. Drug Metab. Dispos. 29:1325-1331.
10. Elvelin, L. and Elmfeldt, D. (1989). Felodipine: A review of its pharmacological and clinical properties. Drugs Today 25:589-596.
11. Epstein, M. (ed.) (2002). Calcium Antagonists in Clinical Medicine. Hanley and Belfus, Philadelphia, PA.
12. Evans, B. E., Rittle, K. E., Bock, M. G., DiPardo, R. M. et al. (1988). Methods for drug discovery: Development of potent, selective, orally effective cholecystokinin antagonists. J. Med. Chem. 31:2235-2246.
13. Fleckenstein, A. (1983). Calcium Antagonism in Heart and Smooth Muscle. Wiley, New York.
14. ATP potassium channel openers. Bioorg. Med. Chem. Lett. 3:2725-2726.
15. Godfraind, T., Salomone, S., Dessy, C., Verhelst, B., Dion, R., and Schoemerts, J. C. (1992). Selectivity scale of calcium antagonists in the human cardiovascular system based on in vitro studies. J. Cardiovasc. Pharmacol. 20(Suppl. 5): S34-S41.
16. Goldmann, S., and Stoltefuss, J. (1991). 1,4-Dihydropyridines: Effects of chirality and conformation on the calcium antagonist and agonist activities. Angew. Chem. Int. Ed. 30:1559-1578.
17. 1a-adrenergic receptor determines subtype selectivity of dihydropyridine antagonists. Biochemistry 35:14312-14317.
18. Hockerman, G. H., Peterson, B. Z., Johnson, B. D., and Catterall, W. A. (1997). Molecular determinants of drug binding and action on L-type calcium channels. Annu. Rev. Pharmacol. 37:361-396.
19. Hu, H., and Marban, E. (1998). Isoform-specific inhibition of L-type calcium channels by dihydropyridines is independent of isoform-specific gating properties. Mol. Pharmacol. 53: 902-907.
20. Ito, H., Klugbauer, H., and Hofmann, F. (1997). Transfer of the high affinity dihydropyridine sensitivity from L-type to non-L-type calcium channel. Mol. Pharmacol. 52:735-740.
21. 3 adenosine receptor antagonists. J. Med. Chem. 42:3055-3065.
22. 3 adenosine receptor antagonists. J. Med. Chem. 40:2596-2608.
23. 3 adenosine receptor antagonists. J. Med. Chem. 39:4667-4675.
24. 3 muscarinic receptors. Biochem. Pharmacol. 22:267-270.
25. 1C L-type calcium channel. Pflug. Arch. 440:50-60.
26. Lavilla, R. (2002). Recent developments in the chemistry of dihydropyridines. J. Chem. Soc., Perkin Trans. 1:1141-1156.
27. ATP channel activator. Cardiovasc. Drug Rev. 15:220-231.
28. Lopez, M. G., Fonteriz, R. I., Gandia, L., de la Fuente, M., Villarroya, M., Garcia-Sancho, J., and Garcia, A. G. (1993). The nicotinic acetylcholine receptor of the bovine chromaffin cell, a new target for 1,4-dihydropyridines. Eur. J. Pharmacol. 247:199-207.
29. Malstrom, R. E., Balmer, K. C., Weilitz, J., Nordlander, M., and Sjolander, M. (2001). Pharmacology of H 394/84, a dihydropyridine neuropeptide Y Y1 receptor antagonist in vivo. Eur. J. Pharmacol. 418:95-104.
30. Mann, J. (1992). Murder Magic and Medicine. Oxford University Press, Oxford.
31. 2+ channel agonists with the human thromoboxane A2/Prostaglandin H2 receptor. Eur. J. Pharmacol. 206:15-21, 1996.
32. 1 subunits. Br. J. Pharmacol. 125:1005-1012.
33. Nagarathnam, D., Wetzel, J. M., Miao, S. W., Marzbadi, M. R., Chiu, G., Wong, W. C., Hong, X., Fang, J., Forray, C., Branchek, T. A., Heydorn, W. A., Chang, R. S. L., Broten, T., Schorn, T. W., and Gluchowski, C. (1998). Design and synthesis of novel a1a adrenoceptor-selective dihydropyridine antagonists for the treatment of benign prostatic hyperplasia. J. Med. Chem. 41:5320-5333.
34. Nelson. D. M., and Cox, M. M. (2000). Lehninger: Principles of Biochemistry. Worth Publishers, New York.
35. Olivera, B. M. (1999). Speciation of cone smails and interspecific hyperdivergence of their venom peptides. Potential evolutionary significance of introns. Ann. N.Y. Acad. Sci. 870:223-237.
36. Patchett, A. A., and Nargund, R. P. (2000). Privileged structures - An update. Ann. Rep. Med. Chem. 35:289-298.
37. Pointdexter, G. S., Bruce, M. A., LeBoulluec, K. L., Monkouic, I., Martin, S. W., Parker, E. M., Iben, L. G., McGovern, R. T., Ortiz, A. A., Stanley, J. A., Mattson, G. K., Kozlowski, M., Arcuri, M., and Antal-Zimanyi, I. (2002). Dihydropyridine neuropeptide Y Y1 receptor antagonists. Biorg. Med. Chem. Lett. 12:379-382.
38. Schreiber, S. (2000). Target-oriented and diversity-oriented organic synthesis in drug discovery. Science 287:1964-1969.
39. Shen, G. S., Layer, R. T., and McCabe, R. T. (2000). Conopeptides: From deadly venoms to novel therapeutics. Drug Discovery Today 5:98-106.
40. Shibasaki, K., Uchida, W., Takizawa, K., Masuda, N., Okazaki, T., Inagaki, O., Asano, M., and Takenaka, T. (1997). Cardiovascular effects of YM 430,a 1,4-dihydropyridine derivative with beta-adrenoceptor blocking activity, in dogs and rats. Biol. Pharm. Bull. 20:230-236.
41. 1188. J. Biol. Chem. 272:27686-27693.
42. Skeen, G. A., Twyman, R. E., and White, H. S. (1993). The dihydropyridine nitrendipine modulates N-methyl-D-aspartate receptor channel function in mammalian neurons. Mol. Pharmacol. 44:443-450.
43. Skeen, G. A., White H. S., and Twyman, R. E. (1994). The dihydropyridine nitrendipine reduces N-methyl-D-aspartate (NMDA)-evoked currents of rodent cortical neurons through a direct interaction with the NMDA receptor-associated ion channel. J. Pharmacol. Exp. Ther. 271:30-38.
44. 2+ channels. Trends Pharmacol. Sci. 19:108-115.
45. Sunkel, C. E., de Casa-Juana, M. D. de, Cillero, F. J., Priego, J. G., and Ortega, M. P. (1988). Synthesis, platelet aggregation inhibitory activity, and in vivo antithrombotic activity of new 1,4-dihydropyridines. J. Med. Chem. 31:1886-1890.
46. Sunkel, C. E., Casa-Juana, M. F. de, Santos, L., Gomez, M. M., Villarroya, M., Gonzalez-Morales, M. A., Priego, J. G., and Ortega, M. P. (1990). 4-Alkyl-1,4-dihydropyridines derivatives as specific PAF-Acether antagonists. J. Med. Chem. 33:3205-3210.
47. Triggle, D. J. (1990). Calcium antagonists. History and perspective. Stroke 21(Suppl. IV):IV49-IV58.
48. Triggle, D. J. (2002). Mechanisms of action of calcium antagonists. In Epstein, M. (ed.), Calcium Antagonists in Clinical Medicine, Hanley and Belfus, Philadelphia, pp. 1-32.
49. Triggle, D. J. (2003a). The 1,4-dihydropyridine nucleus: A pharmacophoric template. MiniRev. Med. Chem. 3:166-175.
50. Triggle, D. J. (2003b). 1,4-Dihydropyridine calcium channel ligands: Selectivity of action. Drug Discovery Research. 58:5-17.
51. Triggle, D. J., Langs, D. A., and Janis, R. A. (1989). Ca2+ channel ligands: Structure-function relationships of the 1,4-dihydropyridines. Med. Res. Rev. 9:123-180.
52. 3H]-P1075 binding in urinary tract smooth muscle. Res. Commun. Mol. Path. Pharmacol. 88:137-155.
53. 3 receptors. J. Med. Chem. 39:2980-2989.
54. Welling, A., Kwan, Y. K., Bosse, E., Flockerzi, V., Hofmann, F., and Kass, R. S. (1993). Subunit-dependent modulation of recombinant L-type calcium channels. Circ. Res. 73:974-980.
55. Wess, G., Urmann, M., and Sickenerger, B. (2001). Medicinal chemistry: Challenges and opportunities. Angew. Chem. 40:3341-3350.
56. Wiley, R. A., and Rich, D. H. (1993). Peptidomimetics derived form natural products. Med. Res. Rev. 13:327-384.
57. 1a adrenoceptor-selective antagonist that inhibits phenylephrine-induced contraction of the human prostate. J. Med. Chem. 41:2643-2650.
58. 2+ channel sensitivity towards the blocker isradipine is affected by the alternative splicing of the human α1c subunit gene. FEBS Lett. 427:220-234.